RxDoctor Payments Data

Ivan Wong

van Nuys, CANPI 1043472772

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (41.9%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Smith+Nephew accounts for 90.0% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $11,052 and has fallen 98.6% since, to $156 in 2025.

$15,866in general payments, 2019–2025

Across 25 payments — averaging $634.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$14K
  • Medical Device Business Services, Inc.$885
  • Aesculap Biologics, LLC$502
  • Abbott$156
  • Linvatec Corporation$40
$636,496in research payments, 2019–2025

Across 79 payments — averaging $8056.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Aesculap Biologics, LLC$636K
  • Zimmer Biomet$154

What the payments were for

  • Consulting fees$6,65442%
  • Speaking & faculty fees$3,71023%
  • Travel & lodging$4,45328%
  • Food & beverage$1,0497%

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →